Human trials confirmed at Kyoto University Hospital
Phase I safety trials officially commenced with adult male participants. No serious adverse effects reported in initial dose cohort. Trial runs through August 2025.
Read source →Breaking Research • Japan • 2024–2030
What if you could grow back your own teeth?
Scientists in Japan are testing a drug that could make dental implants obsolete. We're tracking every step — from the lab to your dentist's chair.
2024
Human trials began
2030
Target launch date
1st
Of its kind in the world
The Science
How does a tooth regrowth drug actually work?
Your body already carries the blueprint for a third set of teeth. Deep in your jaw are dormant tooth buds — suppressed by a protein called USAG-1 (Uterine Sensitization Associated Gene-1) that tells them to stay quiet.
Researchers at Kyoto University, working through Toregem Biopharma, developed an antibody drug that blocks USAG-1. Without that suppression signal, those dormant buds can activate and grow into real, natural teeth — your own biological tissue, not a titanium implant.
It's already worked in mice, ferrets, and as of October 2024, Phase I human trials have begun in Kyoto. The results so far: no serious side effects, and the mechanism is holding up exactly as the science predicted.
See the full development timeline →
Illustration: USAG-1 protein inhibition activates dormant tooth buds in the jaw
Development Timeline
From mouse to medicine
A decade of research is approaching a turning point. Here's where things stand.
-
2018
Mouse experiments succeed
Toregem scientists successfully regrow teeth in mice by blocking USAG-1. The dormant bud theory is confirmed in living animals for the first time.
-
2021–2023
Ferret & primate trials
The antibody drug works across species, including animals with more human-like dental anatomy. Confidence grows that the mechanism will translate to people.
-
October 2024
Phase I human trials begin
Kyoto University Hospital begins testing on 30 adult males (ages 30–64) with missing teeth. Primary goal: confirm safety. Single doses injected into gum tissue.
-
2025 → Now
Children's trial underway
A second trial tests children (ages 2–7) born with congenitally missing teeth — who are thought to have the most viable dormant buds. This is the cohort most likely to show visible regrowth.
Active -
2026–2029
Phase II & III trials
Larger trials across broader adult populations. Regulatory review begins in Japan, followed by FDA and EMA submissions for US and European markets.
-
Target: 2030
Commercial launch
Toregem Biopharma's official target for making the drug available — first in Japan, then globally pending regulatory approvals. A multi-billion dollar dental implant industry would be permanently disrupted.
Latest Updates
What's happening now
We track every development from research journals, clinical trial registries, and global dental news.
PubMed study confirms USAG-1 antibody approach for congenital hypodontia
Peer-reviewed publication confirms the scientific framework is sound, with Phase I protocol finalized.
Read study →General use targeted for 2030, say Kyoto researchers
Dentistry Today reports the research team is on track and confident in their 2030 commercialization timeline.
Read article →Trial begins for children with congenital tooth agenesis
Kids born without adult teeth — who may have the most viable dormant buds — are now part of the next trial phase.
Read article →Be first to know when this reaches the US
The drug is on track for a 2030 launch. We'll notify you about every major milestone — trial results, FDA filings, approval dates, and when you can actually talk to your dentist about it.
Questions
What people want to know
- Will this work for adults who lost teeth to decay or injury?
- That's the goal of the adult trials currently underway. The Phase I cohort consists of adults with missing teeth. Early signals are promising, though Phase II trials — focused on efficacy in adults — will tell us more.
- Is this available anywhere right now?
- No. The drug is in Phase I clinical trials in Japan. It is not available for public use anywhere in the world. The earliest realistic date for commercial availability is 2030, and that's in Japan first — US and EU approval would follow.
- Could this make dental implants obsolete?
- Potentially, for many patients. Dental implants are a $6 billion+ global industry. A drug that grows biological teeth from dormant buds would be a superior solution — no surgery, no titanium, no bone grafting. It's why the dental industry is watching this closely.
- Who is behind this research?
- The drug was developed by researchers at Kyoto University, led by Dr. Katsu Takahashi. It is now being commercialized through Toregem Biopharma Co., Ltd., a Kyoto-based biotech. Clinical trials are being conducted at Kyoto University Hospital.